Starling Takes Flight: The Oncology Institute's Rebrand, Refinancing, and a Delegated Model Going National
Q2 delivered the second profitable quarter as a public company and a de-risking refinancing, while new capitated wins in Nevada, Oregon, and California took the delegated model beyond Florida — the tape is paying +103% over 90 days.
TOI · Earnings Call · 2026-08-06
A Rebrand at the Inflection Point
The Oncology Institute opened its second-quarter call with news that is at once symbolic and strategic: it is now Starling Oncology, a name drawn from the murmurations of starlings flying in coordinated formation — the metaphor for the coordinated, value-based cancer care it claims as its mission.
As we have transformed this business over the past several years, our prior name no longer reflected our scope as a national value-based oncology leader.
The rebrand lands at a genuine inflection rather than a cosmetic one. The company reported “our second profitable quarter as a public company” — Daniel Virnich · 2026-08-06 and, in the same breath, reshaped its risk profile. “We completed a strategic refinancing with OrbiMed in July following repaying the $86 million senior secured convertible note that had been outstanding,” — Rob Carter · 2026-08-06 replacing it with a $75 million term loan plus about $11 million of cash, extending maturities from 2027 to 2031 while avoiding equity dilution. For a balance sheet running liabilities at well over 100% of assets, this strategic refinancing buys the runway to grow into the leverage — a meaningful de-risking of the whole story.
The Delegated Model Goes National
The growth engine is the delegated arrangements, and the quarter's announcements show them breaking out of Florida. Management flagged three new delegated capitated contracts at the start of Q4 — two of them in Nevada and Oregon — representing roughly 80,000 additional aggregate lives and about $50 million in annualized capitated revenue.
“Those are both delegated capitation contracts direct to health plan partners. The Oregon contract will be a statewide delegated contract with a health plan. And the Nevada contract will be based in Clark County.” — Daniel Virnich · 2026-08-06
Alongside that sits the more striking win: exclusivity in California with one of the company's largest partners across all of its delegated medical groups, converting a previously split relationship into roughly 230,000 incremental capitated lives. The driver, per the CEO, was execution rather than price:
“What mainly led to that win was just outperforming on service, providing better access to members through our expansive network in California, better coordination of care with primary care physicians referring specialists.” — Daniel Virnich · 2026-08-06
A quarter ago, the story was still about new payer logos — “The patients that we have now capitated through Humana and CarePlus are net new payer partner adds.” — Daniel Virnich, CEO · 2026-03-13 The shift from fresh logos to exclusivity and statewide contracts inside existing relationships is the tell: the model is maturing from vendor into a strategic fixture within partners' networks.
The Numbers Follow
Revenue of $161.3 million was up 35% year-over-year, Specialty Pharmacy grew 58%, and adjusted EBITDA turned positive for the second straight quarter. Management also began disclosing a consolidated medical loss ratio — “MLR for the second quarter was 85.5% compared to 71% a year ago” — Rob Carter · 2026-08-06 — with a 12-month target of 80–90% as delegated lives ramp. That is a critical datapoint for investors watching oncology cost trends rise industry-wide.
Yet the quarter is not without tension. Patient Services gross profit fell roughly 57% year-over-year to $2.1 million as clinical labor was added ahead of contract launches and MLR naturally rises while onboarding new lives. In the prior quarter, management was already sizing the delegated book at “performing slightly better than our target MLR of 85%” — Daniel Virnich, CEO · 2026-05-08 — the new disclosure merely makes the quarterly volatility visible.
Total revenue has compounded to a record as the model layers new lives and pharmacy attach.
The tape is rewarding the story: the stock is up roughly 103% over the last 90 trading days, a sharp re-rating from a depressed base. The price-to-sales multiple, while still under 1x, is up 124% year-over-year — the market starting to pay up for the new trajectory.
What Changed, Why It Matters
Oncology Institute — now Starling — has shifted from a cost-cutting turnaround into a growth story with a de-risked balance sheet, an expanding delegated footprint, and a second consecutive quarter of profitability. The raised guidance embeds roughly $150 million of capitation revenue this year, before an expected doubling in 2027. The risks are equally clear: margin compression during onboarding, high leverage, and dependence on a small set of large payers. But for a small-cap that spent four years in drawdown, the combination of a rebrand, a refinancing, and a genuinely new geographic footprint makes this the most consequential quarter in years.